InMed Updates Progress of its Epidermolysis Bullosa Program

New Pre-clinical Results of Pain Relieving Properties of INM-750

Vancouver, BC - May 18, 2016 - InMed Pharmaceuticals Inc. ("InMed") (CSE: IN; OTCQB: IMLFF), a biopharmaceutical company specializing in the research and development of novel, cannabinoid-based therapies is pleased to provide an update on the progress of INM-750, its lead product in development for epidermolysis bullosa (EB), a serious and severe genetically inherited skin disorder.

INM-750 is a topical formulation of phytocannabinoids that has been specifically designed to: (i) modify the underlying cause of the disease in patients with epidermolysis bullosa simplex (EBS, the most common form of the disease), and (ii) to treat the major symptoms of the disease in all patients with EB.

InMed is now pleased to report that INM-750 has demonstrated positive pain relieving effects in animal models. Dr. Sazzad Hossain, Chief Scientific Officer of InMed, stated, "I am very excited with these results as pain is a serious complication in EB and this animal data shows that INM-750 reduces both acute and chronic pain. Significant data has been previously generated and reported to demonstrate the diverse properties of INM-750 in wound healing, skin regeneration, anti-inflammation and its antibacterial effects. Together with pain, these disease hallmarks are key therapeutic targets for the effective treatment of EB as well as several other dermatological conditions." 

A summary of the pre-clinical results on INM-750, a non-THC cannabinoid based composition, is available on InMed's website under the Investors and the Pipeline sections.

About Epidermolysis bullosa simplex (EBS) 

Epidermolysis bullosa simplex (EBS) is one of the major forms of epidermolysis bullosa (EB), a group of genetic conditions that cause the skin to be very fragile and to blister easily. It is a result of a defect in anchoring between the epidermis and the dermis, resulting in severe skin fragility that can range from mild to lethal. There is no cure or approved treatments for EB. Wound care, pain management and preventative bandaging are currently the only options available. 

About InMed

InMed is a preclinical stage biopharmaceutical company that specializes in developing novel therapies through the research and development into the pharmacology of cannabinoids combined with innovative drug delivery systems. InMed's proprietary platform technology, product pipeline and accelerated development pathway are the fundamental value drivers of the company. For more information, visit

CONTACT: Investors

Chris Bogart
Interim Chief Executive Officer 
Tel: 604.669.7207

Forward Looking Statements

This news release may contain forward-looking statements and information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management's reasonable assumptions, there can be no assurance that such assumptions will prove to be correct. We assume no responsibility to update or revise them to reflect new events or circumstances.

Additionally, there are known and unknown risk factors which could cause InMed Pharmaceuticals actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein. 

All forward-looking information herein is qualified in its entirety by this cautionary statement, and InMed Pharmaceuticals disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.

These risks and uncertainties include, among others, the possibility that clinical trials will not be successful, or be completed, or confirm earlier clinical trial results, risks associated with obtaining funding from third parties, risks related to the timing and costs of clinical trials and the receipt of regulatory approvals.